ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
29 avr. 2024 07h57 HE
|
ZyVersa Therapeutics
NLRP1 & pyrin govern inflammation in Alzheimer’s Disease, and release of inflammasome laden extracellular vesicles induces cardiovascular inflammation.